Tags

Type your tag names separated by a space and hit enter

Cidofovir in the treatment of poxvirus infections.
Antiviral Res 2002; 55(1):1-13AR

Abstract

Cidofovir [(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, HPMPC] has since 1996 been licensed for clinical use in the treatment of cytomegalovirus (CMV) retinitis in AIDS patients. Cidofovir has broad-spectrum activity against virtually all DNA viruses, including herpes-, adeno-, polyoma-, papilloma- and poxviruses. Among the poxviruses, vaccinia, variola (smallpox), cowpox, monkeypox, camelpox, molluscum contagiosum and orf have proven sensitive to the inhibitory effects of cidofovir. In vivo, cidofovir has shown high efficacy, even after administration of a single systemic (intraperitoneal) or intranasal (aerosolized) dose, in protecting mice from a lethal respiratory infection with either vaccinia or cowpox. Cidofovir has also demonstrated high effectiveness in the treatment of vaccinia virus infection in severe combined immune deficiency mice. In humans, cidofovir has been used successfully in the treatment, by both the topical and intravenous route, of recalcitrant molluscum contagiosum and orf in immunocompromised patients. Taken together, these data indicate that cidofovir should be effective in the therapy and short-term prophylaxis of smallpox and related poxvirus infections in humans, as well as the treatment of the complications of vaccinia that may arise in immunocompromised patients inadvertently inoculated with the smallpox vaccine (vaccinia).

Authors+Show Affiliations

Rega Institute for Medical Research, Katholieke Universiteit Leuven, Minderbroedersstraat 10, B-3000, Leuven, Belgium. erik.declercq@rega.kuleuven.ac.be

Pub Type(s)

Comparative Study
Journal Article
Review

Language

eng

PubMed ID

12076747

Citation

De Clercq, Erik. "Cidofovir in the Treatment of Poxvirus Infections." Antiviral Research, vol. 55, no. 1, 2002, pp. 1-13.
De Clercq E. Cidofovir in the treatment of poxvirus infections. Antiviral Res. 2002;55(1):1-13.
De Clercq, E. (2002). Cidofovir in the treatment of poxvirus infections. Antiviral Research, 55(1), pp. 1-13.
De Clercq E. Cidofovir in the Treatment of Poxvirus Infections. Antiviral Res. 2002;55(1):1-13. PubMed PMID: 12076747.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cidofovir in the treatment of poxvirus infections. A1 - De Clercq,Erik, PY - 2002/6/22/pubmed PY - 2003/2/14/medline PY - 2002/6/22/entrez SP - 1 EP - 13 JF - Antiviral research JO - Antiviral Res. VL - 55 IS - 1 N2 - Cidofovir [(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, HPMPC] has since 1996 been licensed for clinical use in the treatment of cytomegalovirus (CMV) retinitis in AIDS patients. Cidofovir has broad-spectrum activity against virtually all DNA viruses, including herpes-, adeno-, polyoma-, papilloma- and poxviruses. Among the poxviruses, vaccinia, variola (smallpox), cowpox, monkeypox, camelpox, molluscum contagiosum and orf have proven sensitive to the inhibitory effects of cidofovir. In vivo, cidofovir has shown high efficacy, even after administration of a single systemic (intraperitoneal) or intranasal (aerosolized) dose, in protecting mice from a lethal respiratory infection with either vaccinia or cowpox. Cidofovir has also demonstrated high effectiveness in the treatment of vaccinia virus infection in severe combined immune deficiency mice. In humans, cidofovir has been used successfully in the treatment, by both the topical and intravenous route, of recalcitrant molluscum contagiosum and orf in immunocompromised patients. Taken together, these data indicate that cidofovir should be effective in the therapy and short-term prophylaxis of smallpox and related poxvirus infections in humans, as well as the treatment of the complications of vaccinia that may arise in immunocompromised patients inadvertently inoculated with the smallpox vaccine (vaccinia). SN - 0166-3542 UR - https://www.unboundmedicine.com/medline/citation/12076747/Cidofovir_in_the_treatment_of_poxvirus_infections_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0166354202000086 DB - PRIME DP - Unbound Medicine ER -